Effects of Motivating People With Schizophrenia to Exercise
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00559572|
Recruitment Status : Completed
First Posted : November 16, 2007
Last Update Posted : January 16, 2013
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Behavioral: Motivational group sessions Other: Time and attention control group sessions||Not Applicable|
Schizophrenia is a chronic brain disorder that affects about 1% of Americans. People with schizophrenia experience extreme paranoia, often claiming that they hear voices not heard by others and that others are invading or controlling their minds with the intent to hurt them. More specific symptoms include hallucinations, delusional behaviors, disordered movements, and decreased ability to comprehend and apply information to everyday activities. The severity of these symptoms makes self-care and regular exercise difficult for people with schizophrenia. The fatality rate from diabetes, heart disease, and other obesity-related illnesses is significantly higher in people with schizophrenia. Exercise is known to reduce health problems associated with obesity, yet few studies have encouraged exercise as a treatment method for improving the health of those with schizophrenia. Furthermore, the long-term physical and mental effects of consistent exercise on people with schizophrenia are not well-known. This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their attendance, persistence, and compliance to a walking program.
Participants in this study will be randomly assigned to one of two groups. Both groups will continue their regular medications and treatments throughout the study. Upon entry, members of both groups will complete the same two forms concerning attitudes toward exercise. Group 1 participants will attend weekly 1-hour exercise information sessions for 4 weeks. Group 2 participants will attend weekly 1-hour general health information sessions for the same 4 weeks. Participants of both groups will then take part in identical 16-week walking programs. The walking program will consist of three 30- to 50-minute walks per week, including 10 minutes of warm up and 10 minutes of cool down stretching. All participants will gradually increase their walking time from 5 minutes to 30 minutes during the program. At the completion of the walking programs, participants of both groups will complete repeat forms about their attitudes toward exercise. There will be no follow-up visits for the participants.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Motivating Persons With Schizophrenia to Exercise|
|Study Start Date :||November 2007|
|Actual Primary Completion Date :||August 2009|
|Actual Study Completion Date :||August 2009|
Exercise information group
Behavioral: Motivational group sessions
Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
Active Comparator: 2
General health information group
Other: Time and attention control group sessions
Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
- Exercise group attendance [ Time Frame: Measured at Week 16 ]
- Exercise group persistence [ Time Frame: Measured at Weeks 4,8, 12 & 16 ]
- Exercise group compliance [ Time Frame: Measured at Weeks 4,8,12 & 16 ]
- Exercise attitude [ Time Frame: Measured at Weeks 4,8,12 and 16 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00559572
|United States, Tennessee|
|Helen Ross McNabb Center|
|Knoxville, Tennessee, United States, 37917|
|Principal Investigator:||Lora L. Beebe, PhD, PMHNP, BC||University of Tennessee|